Solvanix
Darlinghurst
About Solvanix
Solvanix is a biotechnology company that improves stability and reducing the aggregation of fully human antibodies. Traditional monoclonal and fragment antibodies can have limited stability and a tendency to aggregate, which greatly impacts manufacturability, formulation and product quality. Solvanix’ proprietary StAbilize™ technology works by boosting stability and reducing aggregation of monoclonal antibodies, antibody fragments and bi-specifics. The Company is working with its biotech and pharma partners to improve their therapeutic antibodies and is providing licenses to the StAbilize™ technology.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Funding stage: Seed
- Last round: Seed (Jan 2015)
- Website: solvanix.com
- Phone: (206)938-5850
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/solvanix-1828350 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.